Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results

Autor: Sheldon Freedman, James Bailen, Alan Hay, Frederick Snoy, Richard Levin, Mohamed Bidair, Kenneth Goldberg, Neal D. Shore, Susan Kalota, Ronald F. Tutrone, Jonathan I. Epstein, Steven A. Kaplan

Publikováno v: World Journal of Urology

Purpose This study was undertaken to determine the safety and efficacy of fexapotide triflutate (FT) 2.5 mg and 15 mg for the treatment of Grade Group 1 prostate cancer. Methods Prospective randomized transrectal intraprostatic single injection FT 2.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::102437b4f82242dfe77ce6634378349a
https://doi.org/10.1007/s00345-020-03127-w

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Autor: Renato D. Lopes, Celestia S. Higano, Susan F. Slovin, Adam J. Nelson, Robert Bigelow, Per S. Sørensen, Chiara Melloni, Shaun G. Goodman, Christopher P. Evans, Jan Nilsson, Deepak L. Bhatt, Noel W. Clarke, Tine K. Olesen, Belinda T. Doyle-Olsen, Henriette Kristensen, Lauren Arney, Matthew T. Roe, John H. Alexander, Mirjam Mol-Arts, Samreen Mansor-Lefebvre, Konstantin Zubovskiy, Allan Blemings, Klaus Dugi, Gerald Bloomfield, Chris Kontos, Adam DeVore, Dedrick Jordan, Bradley Kolls, Robin Matthews, Rajendra Mehta, Thomas J. Povsic, Michael Morse, Kenneth W. Mahaffey, Susan Halabi, Darryl Leong, Laurence Klotz, Neil Fleshner, Godfrey Jansz, Jonathan Giddens, Russell Egerdie, Joseph Chin, Joseph Zadra, Richard Casey, Jean Simard, Tamim Niazi, André-Guy Martin, Marek Babjuk, Jaroslav Hajek, Jiri Klecka, Jiri Kubes, Jan Schraml, Jitka Jakesova, Jaroslav Vanasek, Bohuslav Melichar, Heikki Seikkula, Manouar Samir Abdiche, Marc Colombel, Philippe Debourdeau, Gregoire Robert, Arnauld Villers, Guillaume Ploussard, Benjamin Pradere, Franck Bruyere, Jean-Luc Descotes, Idir Ouzaid, Alexander Winter, Herbert Hanitzsch, Herbert Sperling, Ralf Eckert, Peter Hammerer, Elke Stagge, Florian Seseke, Silvio Szymula, Aristotelis Bamias, Anastasios Thanos, Konstantinos Hatzimouratidis, Charalambos Mamoulakis, Haralabos Kalofonos, Elzbieta Oszukowska, Katarzyna Madziarska, Jacek Fijuth, Mateusz Obarzanowski, Boris Alekseev, Vagif Atduev, Dmitri Pushkar, Evgeniy Veliev, Alexander Zyryanov, Sergey Petrov, Evgeny Kopyltsov, Vadim Kozlov, Ladislav Macko, Jozef Dubravicky, Richard Polak, Obaidullah Mir, Marek Vargovcak, Ivan Mincik, Jan Kliment, Frederico Goncalves, Juraj Mikulas, Roman Sokol, Michal Korcek, Jozef Marko, Viktor Kovacik, Igor Milichovsky, Pavol Dubinsky, John Lazarus, Sanjay Dixit, Euan Green, Rajaguru Srinivasan, Danish Mazhar, Yeung Ng, Naveed Sarwar, Craig Herman, Frederick Snoy, Robert Given, Ronald Suh, David Lipsitz, James Bailen, Lawrence Gervasi, Idalia Acosta, Laurence Belkoff, Ning Wu, Jeffrey Frankel, Lawrence Karsh, Bryant Poole, David Lieber, Jason Engel, Mohamed Bidair, Steven Rosenberg, Paul Sieber, Adam Perzin, Susan Kalota, Amar Singh, Ralph Henderson, Jeffrey Wayne, Moben Mirza, Richard D’Anna, Fredrick Wolk, Osvaldo Padron, Kathryn Bylow, Jonathan Rubenstein, Benjamin Gartrell, Michael Schwartz, Kalpesh Patel, Ajit Maniam, Thomas Keane, Michael Goodman, Charles Bane, Michael Chung, Stephen Savage, Edward Uchio, Son Nguyen, William Aronson, Rakesh Khanna, Carlton Barnswell

Publikováno v: Circulation. 144(16)

Background: The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial. Methods: In this inter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd9271ccb4eb75e7486635b0056df019
https://pubmed.ncbi.nlm.nih.gov/35312383

Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes

Autor: Barrett E. Cowan, Peter J. Gilling, Paul Anderson, Mohamed Bidair, Eugene V. Kramolowsky, Tev Aho, Neil Barber, Andrew Thomas, Claus G. Roehrborn, Mark A. Sutton

Publikováno v: Urology. 125:169-173

To report 1-year safety and efficacy outcomes after either Aquablation or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) METHODS: This double-blinded, mul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::570e5f4aab2301a5269dbed9e7050e64
https://doi.org/10.1016/j.urology.2018.12.002

Symptom relief and anejaculation after aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial

Autor: Mark Plante, Neil Barber, Eugene V. Kramolowsky, Andrew Trainer, Barrett E. Cowan, Andrew Arther, Leo Doumanian, Ronald P. Kaufman, Paul Anderson, Gopal H. Badlani, Alexis E. Te, Claus G. Roehrborn, Mohamed Bidair, Mark A. Sutton, Andrew Thomas, Tev Aho, Mark DeGuenther, Peter J. Gilling, Mihir M. Desai

Publikováno v: BJU International. 123:651-660

To test the hypothesis that benign prostatic hyperplasia (BPH) robotic surgery with aquablation would have a more pronounced benefit in certain patient subgroups, such as men with more challenging anatomies (e.g. large prostates, large middle lobes)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3498e618dc8d6ea23512e3dd2b898206
https://doi.org/10.1111/bju.14426

Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement

Autor: Stephen Richardson, Kenneth Goldberg, Ronald F. Tutrone, Jed Kaminetsky, Mitchell Efros, Sheldon Freedman, Barry Shepard, Jeffrey Snyder, Susan Kalota, James Bailen, Neal D. Shore, Richard Levin, Steven N. Gange, Alan Hay, Barton Wachs, Mohamed Bidair, Ivan Grunberger

Publikováno v: World Journal of Urology. 36:801-809

These studies were undertaken to determine if fexapotide triflutate 2.5 mg transrectal injectable (FT) has significant long-term (LT) safety and efficacy for the treatment of benign prostatic hyperplasia (BPH). Two placebo controlled double-blind ran

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bca737f293f39353860c510cb25cc13
https://doi.org/10.1007/s00345-018-2185-y